Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend offered something of a respite, such as it is. In any event, the time has come to resume whatever resembles your new routine. Zoom and Skype meetings may be high on the list, yes? So it’s time to fire up the coffee kettle — our choice today is caramel vanilla cream — and get cracking. As always, we have assembled a few tidbits to help you on your journey. We hope all goes well today and, of course, do stay safe …

Novartis (NVS) reached agreement with the Food and Drug Administration to run a Phase 3 clinical trial to evaluate hydroxychloroquine for treating about 440 hospitalized Covid-19 patients, STAT says. The drug will be supplied by Sandoz, its generics unit, and enrollment will begin at more than a dozen sites in the U.S. within the next few weeks. Novartis will make any intellectual property within its control relating to the use of hydroxychloroquine for treating or preventing Covid-19 available through non-exclusive, voluntary licenses or waivers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!